These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 20482774)

  • 1. A novel biomarker TERTmRNA is applicable for early detection of hepatoma.
    Miura N; Osaki Y; Nagashima M; Kohno M; Yorozu K; Shomori K; Kanbe T; Oyama K; Kishimoto Y; Maruyama S; Noma E; Horie Y; Kudo M; Sakaguchi S; Hirooka Y; Ito H; Kawasaki H; Hasegawa J; Shiota G
    BMC Gastroenterol; 2010 May; 10():46. PubMed ID: 20482774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum human telomerase reverse transcriptase messenger RNA as a novel tumor marker for hepatocellular carcinoma.
    Miura N; Maeda Y; Kanbe T; Yazama H; Takeda Y; Sato R; Tsukamoto T; Sato E; Marumoto A; Harada T; Sano A; Kishimoto Y; Hirooka Y; Murawaki Y; Hasegawa J; Shiota G
    Clin Cancer Res; 2005 May; 11(9):3205-9. PubMed ID: 15867214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a novel assay to quantify serum human telomerase reverse transcriptase messenger RNA and its significance as a tumor marker for hepatocellular carcinoma.
    Miura N; Maruyama S; Oyama K; Horie Y; Kohno M; Noma E; Sakaguchi S; Nagashima M; Kudo M; Kishimoto Y; Kawasaki H; Hasegawa J; Shiota G
    Oncology; 2007; 72 Suppl 1():45-51. PubMed ID: 18087181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human telomerase reverse transcriptase messenger RNA (TERT mRNA) as a tumour marker for early detection of hepatocellular carcinoma.
    El-Mazny A; Sayed M; Sharaf S
    Arab J Gastroenterol; 2014 Jun; 15(2):68-71. PubMed ID: 25097049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitive detection of human telomerase reverse transcriptase mRNA in the serum of patients with hepatocellular carcinoma.
    Miura N; Shiota G; Nakagawa T; Maeda Y; Sano A; Marumoto A; Kishimoto Y; Murawaki Y; Hasegawa J
    Oncology; 2003; 64(4):430-4. PubMed ID: 12759542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpha-fetoprotein and human telomerase reverse transcriptase mRNA levels in peripheral blood of patients with hepatocellular carcinoma.
    Kong SY; Park JW; Kim JO; Lee NO; Lee JA; Park KW; Hong EK; Kim CM
    J Cancer Res Clin Oncol; 2009 Aug; 135(8):1091-8. PubMed ID: 19184104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma.
    Marrero JA; Feng Z; Wang Y; Nguyen MH; Befeler AS; Roberts LR; Reddy KR; Harnois D; Llovet JM; Normolle D; Dalhgren J; Chia D; Lok AS; Wagner PD; Srivastava S; Schwartz M
    Gastroenterology; 2009 Jul; 137(1):110-8. PubMed ID: 19362088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of tumor markers in the diagnosis of hepatocellular carcinoma, with special reference to the des-gamma-carboxy prothrombin.
    Grazi GL; Mazziotti A; Legnani C; Jovine E; Miniero R; Gallucci A; Palareti G; Gozzetti G
    Liver Transpl Surg; 1995 Jul; 1(4):249-55. PubMed ID: 9346575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum microRNA panels as potential biomarkers for early detection of hepatocellular carcinoma on top of HCV infection.
    Zekri AN; Youssef AS; El-Desouky ED; Ahmed OS; Lotfy MM; Nassar AA; Bahnassey AA
    Tumour Biol; 2016 Sep; 37(9):12273-12286. PubMed ID: 27271989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
    Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
    J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical utility of simultaneous measurement of alpha-fetoprotein and des-γ-carboxy prothrombin for diagnosis of patients with hepatocellular carcinoma in China: A multi-center case-controlled study of 1,153 subjects.
    Song P; Feng X; Inagaki Y; Song T; Zhang K; Wang Z; Zheng S; Ma K; Li Q; Kong D; Wu Q; Zhang T; Zhao X; Hasegawa K; Sugawara Y; Kokudo N; Tang W;
    Biosci Trends; 2014 Oct; 8(5):266-73. PubMed ID: 25382443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic Evaluation of Des-Gamma-Carboxy Prothrombin versus α-Fetoprotein for Hepatitis B Virus-Related Hepatocellular Carcinoma in China: A Large-Scale, Multicentre Study.
    Ji J; Wang H; Li Y; Zheng L; Yin Y; Zou Z; Zhou F; Zhou W; Shen F; Gao C
    PLoS One; 2016; 11(4):e0153227. PubMed ID: 27070780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-time quantification of human telomerase reverse transcriptase mRNA in liver tissues from patients with hepatocellular cancer and chronic viral hepatitis.
    Satra M; Gatselis N; Iliopoulos D; Zacharoulis D; Dalekos GN; Tsezou A
    J Viral Hepat; 2007 Jan; 14(1):41-7. PubMed ID: 17212643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential fluctuation pattern of serum des-gamma-carboxy prothrombin levels detected by high-sensitive electrochemiluminescence system as an early predictive marker for hepatocellular carcinoma in patients with cirrhosis.
    Shimizu A; Shiraki K; Ito T; Sugimoto K; Sakai T; Ohmori S; Murata K; Takase K; Tameda Y; Nakano T
    Int J Mol Med; 2002 Mar; 9(3):245-50. PubMed ID: 11836630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size.
    Nakamura S; Nouso K; Sakaguchi K; Ito YM; Ohashi Y; Kobayashi Y; Toshikuni N; Tanaka H; Miyake Y; Matsumoto E; Shiratori Y
    Am J Gastroenterol; 2006 Sep; 101(9):2038-43. PubMed ID: 16848811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy.
    Yamamoto K; Imamura H; Matsuyama Y; Hasegawa K; Beck Y; Sugawara Y; Makuuchi M; Kokudo N
    Ann Surg Oncol; 2009 Oct; 16(10):2795-804. PubMed ID: 19669841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Des-γ carboxyprothrombin may not be a good biomarker for hepatocellular carcinoma in those chronically infected with hepatitis B virus with basal core promoter double mutations (T^{1762}, A^{1764}), a prospective study.
    Li GJ; Chen QY; Harrison TJ; Wang XY; Hu LP; Yang QL; Li KW; Fang ZL
    Cancer Biomark; 2017; 18(3):241-248. PubMed ID: 28085009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of serum α-fetoprotein-L3% and des-γ carboxyprothrombin markers in cases with misleading hepatocellular carcinoma total α-fetoprotein levels.
    Hadziyannis E; Sialevris K; Georgiou A; Koskinas J
    Oncol Rep; 2013 Feb; 29(2):835-9. PubMed ID: 23174906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A simultaneous monitoring of Lens culinaris agglutinin A-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin as an early diagnosis of hepatocellular carcinoma in the follow-up of cirrhotic patients.
    Shimauchi Y; Tanaka M; Kuromatsu R; Ogata R; Tateishi Y; Itano S; Ono N; Yutani S; Nagamatsu H; Matsugaki S; Yamasaki S; Tanikawa K; Sata M
    Oncol Rep; 2000; 7(2):249-56. PubMed ID: 10671666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients.
    Lim TS; Kim DY; Han KH; Kim HS; Shin SH; Jung KS; Kim BK; Kim SU; Park JY; Ahn SH
    Scand J Gastroenterol; 2016 Mar; 51(3):344-53. PubMed ID: 26340708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.